Stocks · News reference
Parabilis Medicines presented updated safety and efficacy data for its lead candidate, zolucatetide, at the ESMO Congress 2026, showing strong clinical results in patients with desmoid tumors.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Parabilis Medicines, Inc. announced that its management team, including CEO Dr. Mathai Mammen, will participate in three investor conferences throughout November 2026.
HC Wainwright & Co. has initiated coverage on Parabilis Medicines, Inc. with a "Buy" rating and a price target of $40.00 per share.
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumorsCompany to host